If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy,” said Patrick Horber M.D., president, International, Novartis. “Together with the recent ...
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
Kisqali was approved by the FDA in this setting 5; at ESMO 2024, an updated analysis from NATALEE was presented, showing a deepening invasive disease-free survival benefit 6 "One-third of people ...
Prokidney Corp. ( (PROK) ) has released its Q3 earnings. Here is a breakdown of the information Prokidney Corp. presented to its investors.
Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals ... "This expanded approval will allow us to bring Verzenio ...
Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic leukemia, among other diseases. The Food and Drug Administration (FDA) expanded ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of ...
While Jazz's sleep disorder drugs are approved for the same condition as Lumryz, Xywav has the FDA's expanded nod to treat idiopathic hypersomnia, a rare neurological condition that causes ...
The U.S. Food and Drug Administration (FDA) has approved the fourth ... is also the first product of its kind to expand beyond the face. The approval is backed by data from Phase 3 trials in ...
Larry Biegelsen has given his Buy rating due to a combination of factors, including the recent FDA approval of NovoCure’s Optune for treating non-small cell lung cancer (NSCLC) with a broad label.
After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ... this momentous milestone and expand our solutions for severe ...